WO2021020885A1 - 레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물 - Google Patents
레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물 Download PDFInfo
- Publication number
- WO2021020885A1 WO2021020885A1 PCT/KR2020/010023 KR2020010023W WO2021020885A1 WO 2021020885 A1 WO2021020885 A1 WO 2021020885A1 KR 2020010023 W KR2020010023 W KR 2020010023W WO 2021020885 A1 WO2021020885 A1 WO 2021020885A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- levodopa
- glp
- polymer
- receptor agonist
- pharmaceutical composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Definitions
- the present invention relates to a pharmaceutical composition for the treatment or inhibition of progression of levodopa-induced dyskinesia, and a method of treating or inhibiting the progression of levodopa-induced dyskinesia with the pharmaceutical composition.
- Parkinson's disease is a neurological disorder caused by degeneration of the dopaminergic neuron of the striatum-black matter of the cerebral basal ganglia. It is a disease (Fahn, 2003).
- the drug therapy for Parkinson's disease is primarily a dopamine agonist or dopamine precursor L-3,4-dihydroxyphenylalanine (L-DOPA) therapy is mainly selected and implemented (Olanow et al., 2001).
- L-DOPA L-3,4-dihydroxyphenylalanine
- long-term L-DOPA therapy in Parkinson's disease animal models causes neurotoxicity due to the formation of reactive oxygen species (ROS) and changes in downstream gene/protein expression, and long-term administration of L-DOPA in Parkinson's disease patients. Not only decreases drug efficacy, but also causes dyskinesia, motor fluctuation and other complications (Jankovic, 2005).
- ROS reactive oxygen species
- Dyskinesia is a side effect of abnormal movement caused by confusion caused by reflux waves in motor muscles.40% of patients who have started L-DOPA treatment for 4-5 years, 9-15 years old Symptoms have been reported in 90% of patients (Nutt, 1990; Quinn, 1995). This dyskinesia is called peak-dose dyskinesia because it responds when the concentration of L-DOPA in the brain is highest (Olanow et al., 2004).
- LID Levodopa-Induced Dyskinesia
- levodopa-induced dyskinesia is related to the expression of genes and proteins in the striatum in which the dopamine nerve is destroyed.
- ⁇ FosB protein expression and extracellular signal-regulated kinase 1/2, ERK1/2 phosphorylation has been reported to be highly related (Andersson et al., 2001; Pav ⁇ n N. et al., 2006).
- ERK1/2 phosphorylation by L-DOPA was related to the expression of AIMs (Abnormal involuntary movements, AIMs), which indicates the degree of dyskinesia. (Westin et al., 2007).
- GLP-1 has been shown to be related to cognition and behavior (During et al., 2003).
- a number of studies have suggested GLP-1 receptor agonists as new treatments for degenerative brain diseases including Parkinson's disease, Alzheimer's disease, Huntington's disease, traumatic brain injury, stroke and peripheral neurosis.
- GLB blood-cerebral barrier
- GLP-1 has a short half-life of 1-2 minutes and is a GLP-1-transferrin fusion created to increase the half-life of GLP-1 by approximately 2 days by conferring resistance to the inactivation of GLP-1.
- Protein (GLP-1-Tf) cannot cross the BBB (Kim et al., 2010; Martin et al., 2012).
- Exendin-4 has been shown to improve rotarod performance compared to GLP-1-Tf (Martin et al., 2012), and although its entry speed is limited, it is known to enter the brain from blood (Kastin AJ et al. , 2003). In addition, exendin-4 was not shown to be effective in providing neuroprotection in an MPTP mouse model for Parkinson's disease, even when given daily for 7 days after treatment (Liu et al., 2015).
- An object of the present invention is to provide a pharmaceutical composition for the treatment or prevention of levodopa-induced dyskinesia.
- An object of the present invention is to provide a method for treating or preventing levodopa-induced dyskinesia.
- the GLP-1 receptor agonist (Glucagon-like peptide-1 receptor agonist) of the present invention includes a GLP-1 analog, and more specifically, exendin-4, exenatide, liraglutide, semaglutide , Lixisenatide, duraglutide, albiglutide, epeglenatide, or a combination thereof may be included, but are not limited thereto.
- the controlled-release formulation of the present invention includes a core comprising a GLP-1 receptor agonist and a biodegradable polymer; And a coating layer of this core.
- the biodegradable polymer of the present invention is polylactide, polyglycolide, poly(lactide-co-glycolide), a copolymer of lactide and glycolide, polyorthoester, polyanhydride, polyhydroxybutyric acid.
- a polymer selected from the group consisting of polycaprolactone and polyalkyl carbonate, or a copolymer or mixture of two or more of the polymers, a copolymer of the polymer and polyethylene glycol, and a polymer in which the polymer or copolymer and sugar are bonded -It may be selected from the group consisting of sugar complexes.
- treatment is a concept including improvement in symptoms of levodopa-induced dyskinesia or no further worsening of symptoms.
- prevention is a concept that includes preventing or delaying onset of levodopa-induced dyskinesia despite administration of levodopa.
- the pharmaceutical composition of the present invention has the effect of improving abnormal involuntary movements (AIMs), and the pharmaceutical composition of the present invention has the effect of reducing the side effects of long-term administration of levodopa when administered in combination with levodopa.
- AIMs abnormal involuntary movements
- the present invention provides a method of treating levodopa-induced dyskinesia comprising administering a therapeutically effective amount of a GLP-1 receptor agonist or a controlled-release formulation thereof to a patient with levodopa-induced dyskinesia.
- the present invention provides a method for preventing levodopa-induced dyskinesia comprising administering a prophylactically effective amount of a GLP-1 receptor agonist or a controlled-release preparation thereof to a Parkinson's disease patient who does not develop levodopa-induced dyskinesia. .
- both patients with levodopa-induced dyskinesia and Parkinson's patients who do not develop levodopa-induced dyskinesia may all be patients receiving levodopa.
- the GLP-1 receptor agonist or a controlled-release preparation thereof may be administered simultaneously with levodopa or after administration of levodopa.
- the therapeutically effective amount of the active ingredient in the treatment method of the present invention may be from 0.01 ⁇ g/kg/day to 100 ⁇ g/kg/day.
- a prophylactically effective amount of the active ingredient may be 0.01 ⁇ g/kg/day to 100 ⁇ g/kg/day.
- the GLP-1 receptor agonist includes a GLP-1 analog, and more specifically, exendin-4, exenatide, liraglutide, semaglutide, lixisenatide, duraglu Tide, albiglutide, epeglenatide, or a combination thereof may be included, but are not limited thereto.
- the controlled-release preparation comprises a core comprising the GLP-1 receptor agonist and a biodegradable polymer; And it may be configured to include a coating layer of the core.
- the biodegradable polymer is polylactide, polyglycolide, poly(lactide-co-glycolide), polyorthoester, polyanhydride, which is a copolymer of lactide and glycolide.
- the present invention provides a use of a GLP-1 receptor agonist or a controlled release formulation thereof in the manufacture of a therapeutic agent for levodopa-induced dyskinesia.
- the present invention relates to a pharmaceutical composition for the treatment or prevention of levodopa-induced dyskinesia.
- the GLP-1 receptor agonist of the present invention or a controlled-release formulation thereof has an effect of reducing serious side effects caused by long-term administration of levodopa when co-administered with levodopa, and has an effect of reducing involuntary dyskinesia caused by levodopa.
- FIG. 1 is a diagram showing a drug treatment schedule for a controlled release formulation (PT320) of a GLP-1 receptor agonist according to an example of the present invention over time.
- PT320 controlled release formulation
- FIG. 2 is a graph confirming the effect of reducing AIMs by treatment with a controlled-release preparation (PT320) of a GLP-1 receptor agonist according to an example of the present invention in rats in which lesions were induced with 6-OHDA.
- PT320 controlled-release preparation
- FIG. 3 is a graph confirming the turnover of dopamine (DA) normalized by treatment with a controlled-release formulation (PT320) of a GLP-1 receptor agonist according to an example of the present invention in a striatum.
- DA dopamine
- PT320 controlled-release formulation
- FIG. 4 is a graph confirming the effect of reducing AIMs in a time-dependent manner by treatment with a controlled-release preparation (PT320) of a GLP-1 receptor agonist according to an example of the present invention in LID-induced rats.
- PT320 controlled-release preparation
- the present invention provides a pharmaceutical composition for the treatment or prevention of levodopa-induced dyskinesia comprising a GLP-1 receptor agonist or a controlled-release preparation thereof.
- the GLP-1 receptor agonist includes a GLP-1 analog, and more specifically, exendin-4, exenatide, liraglutide, semaglutide, rick Cisenatide, duraglutide, albiglutide, epeglenatide, or a combination thereof may be included, but are not limited thereto.
- the controlled-release preparation refers to a preparation having excellent bioavailability by effectively controlling the initial release amount of the GLP-1 receptor agonist to enable sustained and sufficient release of the drug.
- the levodopa-induced dyskinesia is involuntary dyskinesia caused by levodopa, and shows a form of choreoathetosis or dystonia occurring in a limb or trunk. Symptoms as described above are common in patients who have used levodopa for a long period of time and, if severe, refer to side effects that cause serious obstacles in daily life.
- treatment refers to any action including improvement of symptoms of levodopa-induced dyskinesia or no further worsening of symptoms.
- prevention refers to any action including preventing or delaying the onset of levodopa-induced dyskinesia despite administration of levodopa.
- administration means introducing a predetermined substance to an individual in an appropriate way
- individual means rats, mice, livestock, etc., including humans who have or may develop levodopa-induced dyskinesia by administration of levodopa Means all animals. As a specific example, it may be a mammal including a human.
- the pharmaceutical composition of the present invention may be in the form of capsules, tablets, granules, injections, ointments, powders or beverages, and is formulated in the form of oral dosage forms such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories and injections. Can be used.
- the formulation of the pharmaceutical composition of the present invention may be prepared in various ways by mixing with a pharmaceutically acceptable carrier. For example, when administered orally, tablets, troches, capsules, elixir, suspension, syrup, wafers, etc. It may be prepared in a form, and in the case of an injection, it may be prepared in a unit dosage ampoule or a multiple dosage form. In addition, the formulation of the pharmaceutical composition of the present invention may be prepared as a solution, suspension, tablet, capsule, sustained release formulation, or the like.
- the pharmaceutical composition of the present invention may contain an active ingredient alone, or may further include one or more pharmaceutically acceptable carriers, excipients, or diluents.
- Pharmaceutically acceptable carriers may be binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, coloring agents, flavoring agents, etc. for oral administration, and buffering agents, preservatives, painless agents, and
- a solubilizing agent, an isotonic agent, a stabilizer, etc. can be mixed and used, and for topical administration, a base agent, an excipient, a lubricant, a preservative, and the like can be used.
- Carriers, excipients and diluents for formulation are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, filler, anti-coagulant, lubricant, wetting agent, fragrance, emulsifier or preservative.
- the route of administration of the pharmaceutical composition of the present invention may be oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal. Not limited.
- the pharmaceutical composition of the present invention can be administered orally or parenterally, and is preferably administered by a parenteral route.
- parenteral administration external use of the skin or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection injection method may be selected.
- the dosage of the pharmaceutical composition of the present invention varies depending on the age, condition and weight of the patient, the degree of disease, the form of the drug, the route and duration of administration, but may be appropriately selected by those skilled in the art.
- the pharmaceutical composition of the present invention is administered at 0.0001 mg to 1000 mg/kg or 0.001 mg to 500 mg/kg per day, and based on the amount of active ingredient, 0.01 to 100 ⁇ g/kg/day, preferably 0.1 to 10 ⁇ g It can be administered to be /kg/day.
- Administration of the pharmaceutical composition of the present invention may be administered once a day, or may be divided several times.
- the above dosage does not in any way limit the scope of the present invention.
- the controlled-release formulation of the present invention includes a core comprising a GLP-1 receptor agonist and a biodegradable polymer; And it means a pharmaceutical composition comprising the coating layer of the core.
- the biodegradable polymer is a generic term for a polymer that is slowly decomposed and discharged when administered into the body and is harmless to the human body.
- polyester series such as PLA, PGA, and PLGA are hydrolyzed in the body and metabolized into lactic acid and glycolic acid, which are harmless to the human body, and biocompatibility and stability are recognized, and the biodegradation rate is also the molecular weight of the polymer.
- polyester-based polymers such as PLGA and PLA may be more preferably used in the present invention.
- the biodegradable polymer is polylactide (PLA), polyglycolide (PGA), poly (lactide-co-glycolide), a copolymer of lactide and glycolide.
- PLA polylactide
- PGA polyglycolide
- PLGA polyorthoester
- polyanhydride polyhydroxybutyric acid
- polycaprolactone polyalkylcarbonate
- PEG polyethylene glycol
- the polymer-sugar complex in the present invention refers to a form in which the above-described polymer is substituted at the hydroxy group position of the sugar.
- the sugar contains one or more, preferably 1 to 8 saccharide units, and each saccharide unit is a monosaccharide or polysaccharide having 3 to 6 hydroxy groups, or a straight chain structure
- the sugar alcohols may include mannitol, pentaerythritol, sorbitol, ribitol, xylitol, and the like.
- the polymer binds to three or more of the hydroxy groups present in the sugar.
- the biodegradable polymer can be used without limitation of viscosity, but if the viscosity is too low, the drug cannot be effectively protected and the initial release amount of the drug increases, and if the viscosity is too high, the overall release amount of the drug is low and the bioavailability decreases. , It is preferable that the intrinsic viscosity is 0.1 to 0.5 dL/g.
- the coating material is used for the purpose of preventing excessive release of the initial drug and increasing bioavailability.
- the controlled release formulation according to the present invention it is present in the form of a coating layer formed on the outside.
- the coating material may be at least one selected from the group consisting of basic amino acids, polypeptides, and organic nitrogen compounds.
- the basic amino acids include arginine, lysine, histidine, and derivatives thereof, and the polypeptide is 2 to 10 amino acids, preferably 2 to 5 amino acids including at least one selected from the group consisting of arginine, lysine and histidine.
- the number of polypeptides may be dogs, and the polypeptide may have basicity due to the number of basic amino acids greater than the number of acidic amino acids among the total number of amino acids.
- the controlled-release formulation of the present invention can be prepared by various methods, and the sustained-release microspheres of the present invention can be prepared by coating the surface of the microspheres with a coating material by suspending them in an aqueous coating material solution during or after the preparation of microspheres.
- the method of manufacturing microspheres according to the present invention may be to use a double emulsion evaporation method (W/O/W method), a single emulsion evaporation method (O/W method), a phase separation method, a spray drying method, and the like.
- the method for preparing exenatide-containing sustained-release microspheres of the present invention comprises the steps of mixing exenatide and a biodegradable polymer to produce a W/O-type emulsion or a homogeneous mixture; And applying the emulsion or a homogeneous mixture to an aqueous solution of a coating material to emulsify it, thereby forming a coating layer.
- the production method of the present invention is a step of forming a primary emulsion (W/O) by emulsifying an aqueous exenatide solution and an organic solvent in which a biodegradable polymer is dissolved. ; Suspending the emulsion in an aqueous coating material solution to form a W/O/W emulsion, heating it to remove and curing the organic solvent, and recovering the cured microspheres, washing with water, and freeze-drying.
- W/O primary emulsion
- the organic solvent may be any organic solvent capable of dissolving the biodegradable polymer and forming an emulsion by mixing with an aqueous solution, for example, 1 selected from the group consisting of acetic acid, chloroform, ethyl acetate, methylene chloride and methyl ethyl ketone. It can be more than a species.
- the coating material is included in the secondary aqueous phase (the external aqueous phase of the W/O/W emulsion), and when the organic solvent is removed and dried, a coating layer is formed on the outside of exenatide and the biodegradable polymer.
- the production method of the present invention comprises the steps of dissolving a biodegradable polymer and exenatide in an organic solvent to prepare a homogeneous mixture; Preparing an emulsion by adding an aqueous coating material solution to the homogeneous mixture, heating to remove the organic solvent, and curing; And recovering the cured microspheres, washing with water, and lyophilizing.
- the organic solvent may uniformly mix the biodegradable polymer and exenatide, and any organic solvent that can be mixed with an aqueous solution to form an emulsion may be used.
- any organic solvent that can be mixed with an aqueous solution to form an emulsion may be used.
- a mixed solvent of at least one solvent selected from the group consisting of dimethyl sulfoxide, and n-methylpyrrolidone and at least one solvent selected from the group consisting of chloroform, ethyl acetate, methyl ethyl ketone, and methylene chloride further
- a mixed solvent of methanol and methylene chloride is used.
- a coating layer is formed on the surface of the final microspheres.
- the production method of the present invention comprises the steps of dissolving a biodegradable polymer and exenatide in an organic solvent to prepare a homogeneous mixture; Preparing an emulsion by adding an aqueous coating material solution to the homogeneous mixture, heating to remove the organic solvent, and curing; And recovering the cured microspheres, washing with water, and lyophilizing.
- the organic solvent may uniformly mix the biodegradable polymer and exenatide, and any organic solvent that can be mixed with an aqueous solution to form an emulsion may be used.
- any organic solvent that can be mixed with an aqueous solution to form an emulsion may be used.
- alcohols having 1 to 5 carbon atoms glacial acetic acid, formic acid
- a mixed solvent of at least one solvent selected from the group consisting of dimethyl sulfoxide and n-methylpyrrolidone and at least one solvent selected from the group consisting of chloroform, ethyl acetate, methyl ethyl ketone, and methylene chloride is used. It is good to do.
- the method for preparing exenatide-containing sustained-release microspheres of the present invention comprises the steps of mixing exenatide and a biodegradable polymer to produce an emulsion or a homogeneous mixture; Powdering the emulsion or homogeneous mixture obtained above to prepare primary microspheres; And suspending the obtained primary microspheres in an aqueous coating material solution to form a coating layer.
- the powdering method is not limited, and all powdering methods commonly used in the related art may be used, for example, a phase separation method or a spray drying method may be used.
- the manufacturing method of the present invention is a step of preparing an emulsion by mixing an exenatide aqueous solution and an organic solvent in which a polymer is dissolved, or mixing exenatide and a polymer with a mixed solvent.
- a homogeneous mixture solution Adding oil such as silicone oil to make primary microspheres; To remove the organic solvent from the microspheres and cure the primary microspheres by adding a non-solvent of a biodegradable polymer, such as a mixed solvent of an alcohol having 1 to 5 carbon atoms and an alkane having 1 to 12 carbon atoms, preferably a mixed solvent of ethanol and heptane Letting go; Suspending the obtained microspheres in an aqueous coating material solution to form a coating layer; And recovering the microspheres on which the coating layer is formed, washing and lyophilizing.
- a biodegradable polymer such as a mixed solvent of an alcohol having 1 to 5 carbon atoms and an alkane having 1 to 12 carbon atoms, preferably a mixed solvent of ethanol and heptane Letting go
- the organic solvent may be at least one selected from the group consisting of chloroform, ethyl acetate, methylene chloride, and methyl ethyl ketone, and preferably methylene chloride.
- the mixed solvent is one or more solvents selected from the group consisting of alcohols having 1 to 5 carbon atoms, glacial acetic acid, formic acid, dimethyl sulfoxide, and n-methylpyrrolidone, and chloroform, ethyl acetate, methyl ethyl ketone,
- it may be a mixed solvent with at least one selected from the group consisting of methylene chloride, preferably a mixed solvent of methanol and methylene chloride.
- the manufacturing method of the present invention is a step of making an emulsion by mixing an aqueous solution of exenatide and an organic solvent in which a polymer is dissolved, or by mixing exenatide and a polymer with a single solvent or a mixed solvent.
- Preparing a solution Spray-drying the solution or emulsion to prepare primary microspheres; It may include the steps of forming a coating layer by suspending the obtained primary microspheres in an aqueous coating material solution, and washing and lyophilizing the obtained coated microspheres with water.
- the organic solvent may be at least one selected from the group consisting of chloroform, ethyl acetate, methylene chloride, and methyl ethyl ketone, and preferably methylene chloride.
- the single solvent is one or more selected from the group consisting of glacial acetic acid or formic acid
- the mixed solvent is a group consisting of an alcohol having 1 to 5 carbon atoms, glacial acetic acid, formic acid, dimethyl sulfoxide, and n-methylpyrrolidone It may be a mixed solvent of at least one solvent selected from among at least one solvent selected from the group consisting of chloroform, ethyl acetate, methyl ethyl ketone, and methylene chloride.
- the manufacturing method of the present invention may further include the step of adding a protective colloidal material by a conventional method, and in specific embodiments, the protective colloidal material may be added when coating the coating material on the microspheres.
- the coating material or aqueous coating material solution dissolved in the aqueous phase used in the production method according to the present invention is used in a concentration of 0.01 M to 1 M, more preferably 0.1 M to 0.5 M. If the concentration of the aqueous coating material solution is lower than the above range, the coating material cannot be sufficiently coated on the surface of the microspheres, and if it is higher than the above range, the coating material becomes a supersaturated solution, and does not improve more than the initial release suppression effect in the saturated solution. , It is preferable that the concentration of the coating material used for producing the microspheres of the present invention is within the above range.
- the controlled release formulation (PT320) containing exenatide of the present invention includes a double emulsification method (W/O/W method), a single emulsification method (O/W method), a phase separation method, a spray drying method, etc. (Korean Patent No. 10-0805208 No. and International Patent Publication No. PCT/US2017/057606), etc.), and in this example, an exenatide-containing controlled release formulation (PT320) was prepared through a spray drying method.
- Each of these as protective colloids was suspended in 0.5M lysine aqueous solution containing 1% (W/V) polyvinyl alcohol (Polyvinyl alcohol, Gohsenol, EG-50), stirred for 3 hours, recovered, washed with distilled water, and lyophilized to form a formulation Got it.
- W/V polyvinyl alcohol
- a diluent including 0.5% sodium carboxymethylcellulose, 5.0% D-mannitol and 0.1% Tween 80 (pH 6.66) was added to 125 mg of PT320 in the powder state obtained through the above process to obtain a PT320 diluent. Used and administered to experimental animal models.
- SR-exenatide (PT320) has the effect of inhibiting the progression of levodopa-induced dyskinesia.
- Example 2-1 Administration route and dosage of SR-exenatide (PT320) and L-DOPA
- the schedules of PT320 and L-DOPA drug treatment are shown in FIG. 1. Referring to this, first, 6-OHDA was injected into the right medial forebrain bundle at 0.25 ⁇ l/min for 10 minutes to induce lesions, and then treated with L-DOPA or L-DOPA+PT320 for 22 days. I did.
- L-DOPA was dissolved in saline with bencerazide (15mg/kg) and administered 6mg/kg/day by intraperitoneal injection (ip), and PT320 (100mg/kg, containing 2mg/kg Exenatide) was administered with L-DOPA.
- sc subcutaneous injection
- each rat was administered 3 hours after L-DOPA administration (Off-medication state) for 1 minute at 30 minute intervals, the following table We observed for 4 types of 1.
- the ALO score means the sum of items 2 to 4, and animals with an ALO cumulative score lower than 10 were excluded from the evaluation.
- the controlled-release formulation (PT320) of the GLP-1 receptor agonist is a composition that reduces AIMs.
- dopamine (DA), dopamine metabolites, and dopamine turnover changed by treatment with a controlled release formulation (PT320) of a GLP-1 receptor agonist according to an example of the present invention were measured by HPLC.
- Example 2 Using the brain of the rat whose behavioral evaluation was completed in Example 2-2, the lesion site and the tissue of the lesion-free area were homogenized in 0.1N perchloric acid (HClO4). Thereafter, centrifugation was performed at 13,000 rpm at 4° C. for 30 minutes to take a supernatant (50 ⁇ l), and then diluted in perchloric acid (1:4, v/v) and injected into HPLC. Tissue concentrations of DA and DA metabolites were analyzed by a coulometric detection system connected to HPLC.
- HEO4 perchloric acid
- the HPLC mobile phase contains methanol (7%), monosodium phosphate (NaH2PO4, 70mM), triethylamine (100 ⁇ l/l), EDTA (0.1mM), sodium octylsulfate (100mg/l) in deionized water and orthophosphoric acid. It was used after adjusting to pH 4.2.
- the mobile phase was analyzed through an HPLC column (Hypersyl, C18, 15cm X 4.6mm, particle size 5 ⁇ m) at a flow rate of 1.2ml/min.
- lesion-induced rats were subjected to apomorphine hydrochloride-induced rotation test (0.5 mg/kg, ip), and systemic rotation toward non-lesion area for the next experiment. All animals exhibiting at least 7 times per minute (7 full body turns/min) were screened. Using the selected animals, a control group treated with 10 mg/kg L-DOPA (i.p.) and 15 mg/kg bencerazide (i.p.) once a day, and PT320 were constructed under the same conditions as the control group. In particular, in the case of the experimental group, PT320 was administered first, and then L-DOPA and bencerazide were administered 1 hour later.
- AIMs were evaluated once a week after PT320 treatment until the 6th week of the experiment, which was evaluated in the same manner as in Example 2-2.
- the final AIMs calculation results according to this evaluation method are shown in FIG. 4.
- SR-exenatide exhibits treatment efficacy in a time-dependent manner in an experimental animal model in which levodopa-induced dyskinesia was induced.
Abstract
Description
4가지 평가 대상 유형 | |
1) 운동 및 회전Locomotor (Lo)& rotation | 병변과 상반되는 운동 증가Increased locomotion contraversive to the lesion |
2) 사지Limb (Li) | 병변과 상반되는 앞다리의 통제 불가능한 무작위 움직임Random uncontrollable movements of forelimb contralateral to the lesion |
3) 입과 혀Orolingual (Ol) | 과도한 씹기와 혀가 돌출된 턱의 움직임Excess chewing and jaw movements with protrusion of the tongue |
4) 축Axial (Ax) | 목과 상반신 반대쪽을 향한 근 긴장 이상Dystonic postures or choreiform twisting of the neck and upper body towards the contralateral side |
구분 | 조건 |
G1(L-Dopa control) | 6OHDA lesion + L-DOPA (10mpk; IP) @ WK 2 + vehicle |
G2(PT320 2wk) | 6OHDA lesion + L-DOPA (10mpk; IP) @ WK 2 + PT320 2mpk @ WK2 |
Claims (20)
- GLP-1 수용체 작용제(Glucagon-like peptide-1 receptor agonist) 또는 그의 방출 제어형 제제를 포함하는 레보도파 유발 이상 운동증의 치료 또는 예방용 약학 조성물.
- 청구항 1에 있어서, 상기 GLP-1 수용체 작용제는 GLP-1 유사체(analogue)인 약학 조성물.
- 청구항 2에 있어서, 상기 GLP-1 유사체는 엑센딘-4, 엑세나타이드, 리라글루타이드, 세마글루타이드, 릭시세나타이드, 두라글루타이드, 알비글루타이드, 에페글레나타이드 또는 이들의 조합인 약학 조성물.
- 청구항 1에 있어서, 상기 방출 제어형 제제는 상기 GLP-1 수용체 작용제와 생분해성 고분자를 포함하는 코어; 및 상기 코어의 코팅층을 포함하는 것인 약학 조성물.
- 청구항 4에 있어서, 상기 생분해성 고분자는 폴리락타이드, 폴리글라이콜라이드, 락타이드와 글라이콜라이드의 공중합체인 폴리(락타이드-코-글라이콜라이드), 폴리오르토에스테르, 폴리안하이드라이드, 폴리하이드록시부티르산, 폴리카프로락톤 및 폴리알킬카보네이트로 이루어진 군에서 선택된 고분자, 상기 고분자 중 2종 이상의 공중합체 또는 혼합물, 상기 고분자와 폴리에틸렌글리콜과의 공중합체, 및 상기 고분자 또는 공중합체와 당이 결합된 고분자-당 복합체로 이루어진 군에서 선택된 것인 약학 조성물.
- 청구항 1에 있어서, 상기 치료는 상기 레보도파 유발 이상 운동증의 증상이 개선되거나 상기 증상이 악화되지 않는 것인, 약학 조성물.
- 청구항 1에 있어서, 상기 예방은 레보도파의 투여에도 불구하고 상기 레보도파 유발 이상 운동증이 발병되지 않거나 지연 발병되도록 하는 것인, 약학 조성물.
- 청구항 1에 있어서, 비자발적 이상 운동(abnormal involuntary movements, AIMs)을 개선하는 효과가 있는 약학 조성물.
- 청구항 1에 있어서, 레보도파와 병용투여가 가능한 약학 조성물.
- 레보도파 유발 이상 운동증 환자에게 치료적으로 유효한 양의 GLP-1 수용체 작용제 또는 그의 방출 제어형 제제를 투여하는 단계를 포함하는 레보도파 유발 이상 운동증의 치료 방법.
- 레보도파 유발 이상 운동증이 발병하지 않은 파킨슨병 환자에게 예방적으로 유효한 양의 GLP-1 수용체 작용제 또는 그의 방출 제어형 제제를 투여하는 단계를 포함하는 레보도파 유발 이상 운동증의 예방 방법.
- 청구항 10 또는 11에 있어서, 상기 환자는 레보도파를 투여하고 있는 환자인, 방법.
- 청구항 10 또는 11에 있어서, 상기 GLP-1 수용체 작용제 또는 그의 방출 제어형 제제는 상기 레보도파와 동시 또는 상기 레보도파 투여 후에 투여되는, 방법.
- 청구항 10에 있어서, 상기 치료적으로 유효한 양은 0.01㎍/kg/day 내지 100㎍/kg/day인, 방법.
- 청구항 11에 있어서, 상기 예방적으로 유효한 양은 0.01㎍/kg/day 내지 100㎍/kg/day인, 방법.
- 청구항 10 또는 11에 있어서, 상기 GLP-1 수용체 작용제는 GLP-1 유사체인, 방법.
- 청구항 16에 있어서, 상기 GLP-1 유사체는 엑센딘-4, 엑세나타이드, 리라글루타이드, 세마글루타이드, 릭시세나타이드, 두라글루타이드, 알비글루타이드 또는 이들의 조합인, 방법.
- 청구항 10 또는 11에 있어서, 상기 방출 제어형 제제는 상기 GLP-1 수용체 작용제와 생분해성 고분자를 포함하는 코어; 및 상기 코어의 코팅층을 포함하는 것인, 방법.
- 청구항 18에 있어서, 상기 생분해성 고분자는 폴리락타이드, 폴리글라이콜라이드, 락타이드와 글라이콜라이드의 공중합체인 폴리(락타이드-코-글라이콜라이드), 폴리오르토에스테르, 폴리안하이드라이드, 폴리하이드록시부티르산, 폴리카프로락톤 및 폴리알킬카보네이트로 이루어진 군에서 선택된 고분자, 상기 고분자 중 2종 이상의 공중합체 또는 혼합물, 상기 고분자와 폴리에틸렌글리콜과의 공중합체, 및 상기 고분자 또는 공중합체와 당이 결합된 고분자-당 복합체로 이루어진 군에서 선택된 것인, 방법.
- 레보도파 유발 이상 운동증의 치료제 제조에 있어서 GLP-1 수용체 작용제 또는 그의 방출 제어형 제제의 용도.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112022001595A BR112022001595A2 (pt) | 2019-07-29 | 2020-07-29 | Composição farmacêutica para tratamento ou inibição da progressão da discinesia induzida por levodopa |
EP20846757.1A EP4005587A4 (en) | 2019-07-29 | 2020-07-29 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA OR SUPPRESSION OF THEIR PROGRESSION |
JP2022505286A JP7336813B2 (ja) | 2019-07-29 | 2020-07-29 | レボドパ誘発性ジスキネジアの治療または進行抑制用の薬学組成物 |
CN202080054823.6A CN114206374A (zh) | 2019-07-29 | 2020-07-29 | 用于治疗左旋多巴诱导的运动障碍或用于抑制其进展的药物组合物 |
CA3148426A CA3148426A1 (en) | 2019-07-29 | 2020-07-29 | Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof |
US17/630,799 US20220273769A1 (en) | 2019-07-29 | 2020-07-29 | Pharmaceutical composition for treating levodopa-induced dyskinesia or for sup-pressing progression thereof |
MX2022001121A MX2022001121A (es) | 2019-07-29 | 2020-07-29 | Composicion farmaceutica para el tratamiento de la disquinesia inducida por levodopa o para la supresion de la progresion de la misma. |
AU2020323820A AU2020323820A1 (en) | 2019-07-29 | 2020-07-29 | Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962879574P | 2019-07-29 | 2019-07-29 | |
US62/879,574 | 2019-07-29 | ||
KR1020200094783A KR102552385B1 (ko) | 2019-07-29 | 2020-07-29 | 레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물 |
KR10-2020-0094783 | 2020-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021020885A1 true WO2021020885A1 (ko) | 2021-02-04 |
Family
ID=74230451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/010023 WO2021020885A1 (ko) | 2019-07-29 | 2020-07-29 | 레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220273769A1 (ko) |
JP (1) | JP7336813B2 (ko) |
AU (1) | AU2020323820A1 (ko) |
BR (1) | BR112022001595A2 (ko) |
CA (1) | CA3148426A1 (ko) |
MX (1) | MX2022001121A (ko) |
WO (1) | WO2021020885A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11865213B2 (en) | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100805208B1 (ko) | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
KR20130043197A (ko) * | 2010-07-20 | 2013-04-29 | 파이토팜 피엘씨 | 엘-도파, 도파민 효능제 및/또는 도파민 증강제 유도된 장애의 치료 |
KR20180096733A (ko) * | 2015-12-23 | 2018-08-29 | 더 존스 홉킨스 유니버시티 | 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제 |
KR20190086460A (ko) * | 2016-10-20 | 2019-07-22 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 신경보호 폴리펩티드를 중추 신경계에 전달하는 방법 |
-
2020
- 2020-07-29 AU AU2020323820A patent/AU2020323820A1/en active Pending
- 2020-07-29 WO PCT/KR2020/010023 patent/WO2021020885A1/ko active Application Filing
- 2020-07-29 CA CA3148426A patent/CA3148426A1/en active Pending
- 2020-07-29 JP JP2022505286A patent/JP7336813B2/ja active Active
- 2020-07-29 MX MX2022001121A patent/MX2022001121A/es unknown
- 2020-07-29 BR BR112022001595A patent/BR112022001595A2/pt unknown
- 2020-07-29 US US17/630,799 patent/US20220273769A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100805208B1 (ko) | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
KR20130043197A (ko) * | 2010-07-20 | 2013-04-29 | 파이토팜 피엘씨 | 엘-도파, 도파민 효능제 및/또는 도파민 증강제 유도된 장애의 치료 |
KR20180096733A (ko) * | 2015-12-23 | 2018-08-29 | 더 존스 홉킨스 유니버시티 | 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제 |
KR20190086460A (ko) * | 2016-10-20 | 2019-07-22 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 신경보호 폴리펩티드를 중추 신경계에 전달하는 방법 |
Non-Patent Citations (2)
Title |
---|
ABUIRMEILEH AMJAD, HARKAVYI ALEXANDER, RAMPERSAUD NAZIR, LEVER REBECCA, TADROSS JOHN A., BLOOM STEPHEN R., WHITTON PETER S.: "Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat : Exendin and L-DOPA dyskinesias", PHARMACEUTICAL AND CLINICAL RESEARCH, JOHN WILEY & SONS LTD, LONDON, GB, vol. 64, no. 5, 1 May 2012 (2012-05-01), GB, pages 637 - 643, XP055776341, ISSN: 0022-3573, DOI: 10.1111/j.2042-7158.2011.01394.x * |
ELABI OSAMA FALAH: "The effect of L-dopa and neuroprotective agents on cell replacement therapy for Parkinson's disease.", CARDIFF UNIVERSITY, 1 January 2017 (2017-01-01), pages 1 - 252, XP055776352 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11865213B2 (en) | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
Also Published As
Publication number | Publication date |
---|---|
JP7336813B2 (ja) | 2023-09-01 |
JP2022544028A (ja) | 2022-10-17 |
CA3148426A1 (en) | 2021-02-04 |
AU2020323820A1 (en) | 2022-03-10 |
BR112022001595A2 (pt) | 2022-03-22 |
US20220273769A1 (en) | 2022-09-01 |
MX2022001121A (es) | 2022-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102552385B1 (ko) | 레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물 | |
CA2588295A1 (en) | Method and composition for administering an nmda receptor antagonist to a subject | |
KR20120098855A (ko) | 청각장애 및 현기증을 치료하기 위한 β-카르볼린 | |
EP2640410B1 (de) | Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase | |
WO2021020885A1 (ko) | 레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물 | |
WO2016190697A1 (ko) | 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물 | |
Desai et al. | Long term therapeutic effects of icariin‐loaded PLGA microspheres in an experimental model of optic nerve ischemia via modulation of CEBP‐β/G‐CSF/noncanonical NF‐κ B axis | |
JPH07316053A (ja) | 末梢神経障害及び中枢神経変性病の処置のための医薬組成物 | |
EP3406259A1 (en) | Neurotrophins for use in the treatment of hearing loss | |
WO2021157968A1 (ko) | 난청 치료용 제어 방출형 제제 및 이의 제조방법 | |
KR20170104457A (ko) | 신경변성 장애 | |
Kong et al. | Neuropeptide S reduces propofol-or ketamine-induced slow wave states through activation of cognate receptors in the rat | |
WO2019066199A1 (ko) | 지속형 팔미트산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물 | |
US10918610B2 (en) | Compounds and methods of promoting myelination | |
WO2023140505A1 (ko) | 할로푸지논을 유효성분으로 함유하는 신경퇴행성 또는 운동신경 질환 예방 또는 치료용 조성물 | |
WO2023210882A1 (ko) | O-사이클릭 피토스핑고신-1-포스페이트 유도체를 유효성분으로 포함하는 면역증진 및 파킨슨병의 예방, 개선 또는 치료용 조성물 | |
WO2024080440A1 (ko) | 휴메닌 펩타이드를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물 | |
WO2022225137A1 (ko) | 자폐 스펙트럼 장애의 예방 또는 치료용 약학적 조성물 및 이를 이용한 자폐 스펙트럼 장애 치료방법 | |
WO2024025321A1 (ko) | 간/지방조직 이중 표적 복합 나노 약물 전달체 | |
US20220296522A1 (en) | Bryoid compositions, methods of making and use thereof | |
WO2023195798A1 (ko) | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 폐섬유증 예방 또는 치료용 조성물 | |
WO2022191658A1 (ko) | 퇴행성 뇌질환 예방 또는 치료용 조성물 | |
WO2021261871A1 (ko) | 6'-하이드록시 저스티시딘-b(6'-hydroxy justicidin b)를 포함하는 호흡기 질환의 예방, 개선 또는 치료용 조성물 | |
WO2023096423A1 (ko) | 징크복합조성물 탑재 마이크로니들 패치를 이용한 항염증 조성물 | |
RU2690188C2 (ru) | Новый мультитаргетный препарат для лечения заболеваний у млекопитающих |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20846757 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3148426 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022505286 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022001595 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022101663 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2020846757 Country of ref document: EP Effective date: 20220228 |
|
ENP | Entry into the national phase |
Ref document number: 2020323820 Country of ref document: AU Date of ref document: 20200729 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112022001595 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220128 |